Abstract
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Phase (P12-12.006)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have